Search

Your search keyword '"Bae, Sang-Cheol [0000-0003-4658-1093]"' showing total 2 results
Start Over Author "Bae, Sang-Cheol [0000-0003-4658-1093]"
2 results on '"Bae, Sang-Cheol [0000-0003-4658-1093]"'

1. 2021 DORIS definition of remission in SLE:Final recommendations from an international task force

Author

Yehuda Schoenfeld, Carlos Vasconcelos, Josef S Smolen, Blanca Rubio, Ricard Cervera, Nathalie Costedoat-Chalumeau, Y K Onno Teng, Søren Jacobsen, Hermine I. Brunner, Mandana Nikpour, Anne Voss, Cindy Coney, Rebecca Fischer, Sang Cheol Bae, M.W.P. Tsang-A-Sjoe, Angela Tincani, Frédéric Houssiau, Elena Zakharhova, Bernadette van Leeuw, Michelle Petri, Eric F Morand, Ian N. Bruce, Maarten Limper, Dimitrios T. Boumpas, Victoria P. Werth, Murat Inanc, Anka Askenase, Ann E. Clarke, Thomas Dörner, Cynthia Aranow, Bernardo A. Pons-Estel, Matthias Schneider, Marta Mosca, László Czirják, George Bertsias, Michael M. Ward, Hendrika Bootsma, Juanita Romero-Diaz, Marzena Olesińska, Guillermo J. Pons-Estel, Xavier Mariette, Andrea Doria, Ruth D E Fritsch-Stork, Graciela S. Alarcón, Eloisa Bonfa, David A. Isenberg, Manuel F. Ugarte-Gil, Annegret Kuhn, Martin Aringer, Laurent Arnaud, Sandra V. Navarra, David Jayne, Anisur Rahman, Raquel Faria, Caroline Gordon, Alexandre E. Voskuyl, Ronald F van Vollenhoven, van Vollenhoven, Ronald F [0000-0001-6438-8663], Doria, Andrea [0000-0003-0548-4983], Morand, Eric [0000-0002-9507-3338], Petri, Michelle A [0000-0003-1441-5373], Pons-Estel, Bernardo A [0000-0003-2518-0266], Ugarte-Gil, Manuel Francisco [0000-0003-1728-1999], Arnaud, Laurent [0000-0002-8077-8394], Bruce, Ian N [0000-0003-3047-500X], Houssiau, Frédéric A [0000-0003-1451-083X], Aringer, Martin [0000-0003-4471-8375], Bae, Sang-Cheol [0000-0003-4658-1093], Boumpas, Dimitrios T [0000-0002-9812-4671], Brunner, Hermine [0000-0001-9478-2987], Dörner, Thomas [0000-0002-6478-7725], Jacobsen, Søren [0000-0002-5654-4993], Teng, Y K Onno [0000-0001-9920-2195], Tsang-A-Sjoe, Michel [0000-0002-4982-3505], Werth, Victoria P [0000-0003-3030-5369], Aranow, Cynthia [0000-0001-9299-0053], Apollo - University of Cambridge Repository, Teng, YK Onno [0000-0001-9920-2195], Jayne, David [0000-0002-1712-0637], UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, and UCL - (SLuc) Service de rhumatologie

Subjects
medicine.medical_specialty, Prednisolone, Immunology, Therapeutics, Disease, Severity of Illness Index, Health care, medicine, therapeutics, Humans, Lupus Erythematosus, Systemic, Medical physics, healthcare, lupus erythematosus, outcome assessment, systemic, Clinical care, skin and connective tissue diseases, Lupus erythematosus, Epidemiology and outcomes, Task force, business.industry, Healthcare, Systemic, Remission Induction, General Medicine, RC581-607, medicine.disease, Clinical trial, Outcome assessment, Research questions, Observational study, Immunologic diseases. Allergy, business, Immunosuppressive Agents
Abstract

ObjectiveTo achieve consensus on a definition of remission in SLE (DORIS).BackgroundRemission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation.MethodsSeveral systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on.ResultsBased on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment ConclusionThe 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.

Published
2021

2. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort

Author

Daniel J. Wallace, Anisur Rahman, Ola Nived, W. Winn Chatham, S. Sam Lim, Søren Jacobsen, Juanita Romero-Diaz, Manuel Ramos-Casals, Michelle Petri, Ronald F van Vollenhoven, Rosalind Ramsey-Goldman, Graciela S. Alarcón, Anca Askanase, Mary Anne Dooley, Sang Cheol Bae, Thomas Stoll, Diane L. Kamen, Sasha Bernatsky, Asad Zoma, Caroline Gordon, Vernon T. Farewell, Andreas Jönsen, Jiandong Su, Jorge Sanchez-Guerrero, John G. Hanly, Dafna D. Gladman, Murray B. Urowitz, Murat Ỉnanç, Ann E. Clarke, Guillermo Ruiz-Irastorza, Paul R. Fortin, Cynthia Aranow, David A. Isenberg, Joan T. Merrill, Kenneth C. Kalunian, Ellen M. Ginzler, Christine A. Peschken, Susan Manzi, Kristjan Steinsson, Ian N. Bruce, Munther A. Khamashta, Clinical Immunology and Rheumatology, AII - Inflammatory diseases, AMS - Amsterdam Movement Sciences, AMS - Musculoskeletal Health, Urowitz, Murray B [0000-0001-7506-9166], Gladman, Dafna D [0000-0002-9074-0592], Bae, Sang-Cheol [0000-0003-4658-1093], Fortin, Paul R [0000-0002-7278-2596], Clarke, Ann Elaine [0000-0002-3112-9646], Bernatsky, Sasha [0000-0002-9515-2802], Gordon, Caroline [0000-0002-1244-6443], Hanly, John G [0000-0003-1029-9483], Isenberg, David A [0000-0001-9514-2455], Rahman, Anisur [0000-0003-2346-4484], Alarcón, Graciela S [0000-0001-5190-9175], Petri, Michelle A [0000-0003-1441-5373], Lim, S Sam [0000-0003-2361-0787], Apollo - University of Cambridge Repository, and Rheumatology

Subjects
Adult, Male, Risk, medicine.medical_specialty, Immunology, Comorbidity, Young Adult, Rheumatology, Internal medicine, medicine, Prevalence, Immunology and Allergy, Humans, Lupus Erythematosus, Systemic, Myocardial infarction, Lupus erythematosus, business.industry, Incidence (epidemiology), Incidence, Hazard ratio, Middle Aged, medicine.disease, Atherosclerosis, Confidence interval, Relative risk, Cohort, Female, business, Body mass index
Abstract

Objective: In previous studies, atherosclerotic vascular events (AVEs) were shown to occur in ~10% of patients with systemic lupus erythematosus (SLE). We undertook this study to investigate the annual occurrence and potential risk factors for AVEs in a multinational, multiethnic inception cohort of patients with SLE. Methods: A large 33-center cohort of SLE patients was followed up yearly between 1999 and 2017. AVEs were attributed to atherosclerosis based on SLE being inactive at the time of the AVE as well as typical atherosclerotic changes observed on imaging or pathology reports and/or evidence of atherosclerosis elsewhere. Analyses included descriptive statistics, rate of AVEs per 1,000 patient-years, and univariable and multivariable relative risk regression models. Results: Of the 1,848 patients enrolled in the cohort, 1,710 had ≥1 follow-up visit after enrollment, for a total of 13,666 patient-years. Of these 1,710 patients, 3.6% had ≥1 AVEs attributed to atherosclerosis, for an event rate of 4.6 per 1,000 patient-years. In multivariable analyses, lower AVE rates were associated with antimalarial treatment (hazard ratio [HR] 0.54 [95% confidence interval (95% CI) 0.32–0.91]), while higher AVE rates were associated with any prior vascular event (HR 4.00 [95% CI 1.55–10.30]) and a body mass index of >40 kg/m2 (HR 2.74 [95% CI 1.04–7.18]). A prior AVE increased the risk of subsequent AVEs (HR 5.42 [95% CI 3.17–9.27], P < 0.001). Conclusion: The prevalence of AVEs and the rate of AVE accrual demonstrated in the present study is much lower than that seen in previously published data. This may be related to better control of both the disease activity and classic risk factors.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results